You just read:

Data from Pivotal FIREFISH and SUNFISH Studies Demonstrate Clinical Benefit of Risdiplam in Type 1, 2, & 3 Spinal Muscular Atrophy Patients

News provided by

PTC Therapeutics, Inc.

May 07, 2019, 01:00 ET